[Code of Federal Regulations]
[Title 26, Volume 1]
[Revised as of April 1, 2003]
From the U.S. Government Printing Office via GPO Access
[CITE: 26CFR1.28-1]

[Page 91-99]
 
                       TITLE 26--INTERNAL REVENUE
 
     CHAPTER I--INTERNAL REVENUE SERVICE, DEPARTMENT OF THE TREASURY
 
PART 1--INCOME TAXES--Table of Contents
 
Sec. 1.28-1  Credit for clinical testing expenses for certain drugs for rare diseases or conditions.

    (a) General rule. Section 28 provides a credit against the tax 
imposed by chapter 1 of the Internal Revenue Code. The amount of the 
credit is equal to 50 percent of the qualified clinical testing expenses 
(as defined in paragraph (b) of this section) for the taxable year. The 
credit applies to qualified clinical testing expenses paid or incurred 
by the taxpayer after December 31, 1982, and before January 1, 1991. The 
credit may not exceed the taxpayer's tax liability for the taxable year 
(as determined under paragraph (d)(2) of this section).
    (b) Qualified clinical testing expenses--(1) In general. Except as 
otherwise provided in paragraph (b)(3) of this section, the term 
``qualified clinical testing expenses'' means the amounts which are paid 
or incurred during the taxable year which would constitute ``qualified 
research expenses'' within the meaning of section 41(b) (relating to the 
credit for increasing research activities) as modified by section 
28(b)(1)(B) and paragraph (b)(2) of this section. For example, amounts 
paid or incurred for the acquisition of depreciable property used in the 
conduct of clinical testing (as defined in paragraph (c) of this 
section) are not qualified clinical testing expenses.
    (2) Modification of section 41(b). For purposes of paragraph (b)(1) 
of this section, section 41(b) is modified by substituting ``clinical 
testing'' for ``qualified research'' each place it appears in paragraph 
(2) of section 41(b) (relating to in-house research expenses) and 
paragraph (3) of section 41(b) (relating to contract research expenses). 
In addition, ``100 percent'' is substituted for ``65 percent'' in 
paragraph (3)(A) of section 41(b).
    (3) Exclusion for amounts funded by another person--(i) In general. 
The term ``qualified clinical testing expenses'' shall not include any 
amount which would otherwise constitute qualified clinical testing 
expenses, to the extent such amount is funded by a grant, contract, or 
otherwise by another person (or any governmental entity). The 
determination of the extent to which an amount is funded shall be made 
in light of all the facts and circumstances. For a special rule 
regarding funding between commonly controlled businesses, see paragraph 
(d)(5)(iv) of Sec. 1.28-1.
    (ii) Clinical testing in which taxpayer retains no rights. If a 
taxpayer conducting clinical testing with respect to

[[Page 92]]

the designated drug for another person retains no substantial rights in 
the clinical testing under the agreement providing for the clinical 
testing the taxpayer's clinical testing expenses are treated as fully 
funded for purposes of section 28(b)(1)(C). Thus, for example, if the 
taxpayer incurs clinical testing expenses under an agreement that 
confers on another person the exclusive right to exploit the results of 
the clinical testing, those expenses do not constitute qualified 
clinical testing expenses because they are fully funded under this 
paragraph (b)(3)(ii). Incidental benefits to the taxpayer from the 
conduct of the clinical testing (for example, increased experience in 
the field of human clinical testing) do not constitute substantial 
rights in the clinical testing.
    (iii) Clinical testing in which taxpayer retains substantial rights-
-(A) In general. If a taxpayer conducting clinical testing with respect 
to the designated drug for another person retains substantial rights in 
the clinical testing under the agreement providing for the clinical 
testing, the clinical testing expenses are funded to the extent of the 
payments (and fair market value of any property at the time of transfer) 
to which the taxpayer becomes entitled by conducting the clinical 
testing. The taxpayer shall reduce the amount paid or incurred by the 
taxpayer for the clinical testing expenses that would, but for section 
28(b)(1)(C) constitute qualified clinical testing expenses of the 
taxpayer by the amount of the funding determined under the preceding 
sentence. Rights retained in the clinical testing are not treated as 
property for purposes of this paragraph (b)(3)(iii)(A). If the property 
that is transferred to the taxpayer is to be consumed in the clinical 
testing (for example, supplies), the taxpayer should exclude the value 
of that property from both the payments received and the expenses paid 
or incurred for the clinical testing.
    (B) Drug by drug determination. The provisions of this paragraph 
(b)(3) shall be applied separately to each designated drug tested by the 
taxpayer.
    (iv) Funding for qualified clinical testing expenses determinable 
only in subsequent taxable years. If, at the time the taxpayer files its 
return for a taxable year, it is impossible to determine to what extent 
some or all of the qualified clinical testing expenses may be funded, 
the taxpayer shall treat the clinical testing expenses as fully funded 
for purposes of that return. When the amount of funding for qualified 
clinical testing expenses is finally determined, the taxpayer should 
amend the return and any interim returns to reflect the amount of 
funding for qualified clinical testing expenses.
    (4) Special rule governing the application of section 41(b) beyond 
its expiration date. For purposes of section 28 and this section, 
section 41(b), as amended, and the regulations thereunder shall be 
deemed to remain in effect after December 31, 1988.
    (c) Clinical testing--(1) In general. The term ``clinical testing'' 
means any human clinical testing which--
    (i) Is carried out under an exemption under section 505(i) of the 
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(i)) and the 
regulations relating thereto (21 CFR part 312) for the purpose of 
testing a drug for a rare disease or condition as defined in paragraph 
(d)(1) of this section,
    (ii) Occurs after the date the drug is designated as a drug for a 
rare disease or condition under section 526 of the Federal Food, Drug, 
and Cosmetic Act (21 U.S.C. 360bb),
    (iii) Occurs before the date on which an application for the 
designated drug is approved under section 505(b) of the Federal Food, 
Drug, and Cosmetic Act (21 U.S.C. 355(b)) or, if the drug is a 
biological product (other than a radioactive biological product intended 
for human use), before the date on which a license for such drug is 
issued under section 351 of the Public Health Services Act (42 U.S.C. 
262), and
    (iv) Is conducted by or on behalf of the taxpayer to whom the 
designation under section 526 of the Federal Food, Drug, and Cosmetic 
Act applies.

Human clinical testing shall be taken into account under this paragraph 
(c)(1) only to the extent that the testing relates to the use of a drug 
for the rare disease or condition for which the drug was designated 
under section 526 of the Federal Food, Drug, and Cosmetic Act. For 
purposes of paragraph

[[Page 93]]

(c)(1)(i) of this section the testing under section 505(i) exemption 
procedures (21 CFR part 312) of a biological product (other than a 
radioactive biological product intended for human use) pursuant to 21 
CFR Sec. 601.21 is deemed to be carried out under an exemption under 
section 505(i) of the Federal Food, Drug, and Cosmetic Act.
    (2) Definition of ``human clinical testing.'' Testing is considered 
to be human clinical testing only to the extent that it uses human 
subjects to determine the effect of the designated drug on humans and is 
necessary for the designated drug either to be approved under section 
505(b) of the Federal Food, Drug, and Cosmetic Act and the regulations 
thereunder (21 CFR part 314), or if the designated drug is a biological 
product (other than a radioactive biological product intended for human 
use), to be licensed under section 351 of the Public Health Services Act 
and the regulations thereunder (21 CFR part 601). For purposes of this 
paragraph (c)(2), a human subject is an individual who is a participant 
in research, either as a recipient of the drug or as a control. A 
subject may be either a healthy individual or a patient.
    (3) Definition of ``carried out under'' section 505(i). Human 
clinical testing is not carried out under section 505(i) of the Federal 
Food, Drug, and Cosmetic Act and the regulations thereunder (21 CFR part 
312) unless the primary purpose of the human clinical testing is to 
ascertain the data necessary to qualify the designated drug for sale in 
the United States, and not to ascertain data unrelated or only 
incidentally related to that needed to qualify the designated drug. 
Whether or not this primary purpose test is met shall be determined in 
light of all of the facts and circumstances.
    (d) Definition and special rules--(1) Definition of ``rare disease 
or condition''--(i) In general. The term ``rare disease or condition'' 
means any disease or condition which--
    (A) Afflicts 200,000 or fewer persons in the United States, or
    (B) Afflicts more than 200,000 persons in the United States but for 
which there is no reasonable expectation that the cost of developing and 
making available in the United States (as defined in section 7701(a)(9)) 
a drug for such disease or condition will be recovered from sales in the 
United States (as so defined) of such drug.

Determinations under paragraph (d)(1)(i)(B) of this section with respect 
to any drug shall be made on the basis of the facts and circumstances as 
of the date such drug is designated under section 526 of the Federal 
Food, Drug, and Cosmetic Act. Examples of diseases or conditions which 
in 1987 afflicted 200,000 or fewer persons in the United States are 
Duchenne dystrophy, one of the muscular dystrophies; Huntington's 
disease, a hereditary chorea; myoclonus; Tourette's syndrome; and 
amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease).
    (ii) Cost of developing and making available the designated drug--
(A) In general. Except as otherwise provided in this paragraph 
(d)(1)(ii), the taxpayer's computation of the cost of developing and 
making available in the United States the designated drug shall include 
only the costs that the taxpayer (or any person whose right to make 
sales of the drug is directly or indirectly derived from the taxpayer, 
e.g., a licensee or transferee) has incurred or reasonably expects to 
incur in developing and making available in the United States the 
designated drug for the disease or condition for which it is designated. 
For example, if, prior to designation under section 526, the taxpayer 
incurred costs of $125,000 to test the drug for the rare disease or 
condition for which it is subsequently designated and incurred $500,000 
to test the same drug for other diseases, and if, on the date of 
designation, the taxpayer expects to incur costs of $1.2 million to test 
the drug for the rare disease or condition for which it is designated, 
the taxpayer shall include in its cost computation both the $125,000 
incurred prior to designation and the $1.2 million expected to be 
incurred after designation to test the drug for the rare disease or 
condition for which it is designated. The taxpayer shall not include the 
$500,000 incurred to test the drug for other diseases.
    (B) Exclusion of costs funded by another person. In computing the 
cost of developing and making available in the United States the 
designated drug, the

[[Page 94]]

taxpayer shall not include any cost incurred or expected to be incurred 
by the taxpayer to the extent that the cost is funded or is reasonably 
expected to be funded (determined under the principles of paragraph 
(b)(3)) by a grant, contract, or otherwise by another person (or any 
governmental entity).
    (C) Computation of cost. The cost computation shall use only 
reasonable costs incurred after the first indication of an orphan 
application for the designated drug. Such costs shall include the costs 
of obtaining data needed, and of meetings to be held, in connection with 
a request for FDA assistance under section 525 of the Federal, Food, 
Drug, and Cosmetic Act (21 U.S.C. 360aa) or a request for orphan 
designation under section 526 of that Act; costs of determining 
patentability of the drug; costs of screening, animal and clinical 
studies; costs associated with preparation of a Notice of Claimed 
Investigational Exemption for a New Drug (IND) and a New Drug 
Application (NDA); costs of possible distribution of drug under a 
``treatment'' protocol; costs of development of a dosage form; 
manufacturing costs; distribution costs; promotion costs; costs to 
maintain required records and reports; and costs of the taxpayer in 
acquiring the right to market a drug from the owner of that right prior 
to designation. The taxpayer shall also include general overhead, 
depreciation costs and premiums for insurance against liability losses 
to the extent that the taxpayer can demonstrate that these costs are 
properly allocable to the designated drug under the established 
standards of financial accounting and reporting of research and 
development costs.
    (D) Allocation of common costs. Costs for developing and making 
available the designated drug for both the disease or condition for 
which it is designated and one or more other diseases or conditions. In 
the case where the costs incurred or expected to be incurred in 
developing and making available the designated drug for the disease or 
condition for which it is designated are also incurred or expected to be 
incurred in developing and making available in the United States the 
same drug for one or more other diseases or conditions (whether or not 
they are also designated or expected to be designated), the costs shall 
be allocated between the cost of developing and making available the 
designated drug for the disease or condition for which the drug is 
designated and the cost of developing and making available the 
designated drug for the other diseases or conditions. The amount of the 
common costs to be allocated to the cost of developing and making 
available the designated drug for the disease or condition for which it 
is designated is determined by multiplying the common costs by a 
fraction the numerator of which is the sum of the expected amount of 
sales in the United States of the designated drug for the disease or 
condition for which the drug is designated and the denominator of which 
is the total expected amount of sales in the United States of the 
designated drug. For example, if prior to designation, the taxpayer 
incurs (among other costs) costs of $100,000 in testing the designated 
drug for its toxic effect on animals (without reference to any disease 
or condition), and if the taxpayer expects to recover $500,000 from 
sales in the United States of the designated drug for disease X, the 
disease for which the drug is designated, and further expects to recover 
another $1.5 million from the sales in the United States of the 
designated drug for disease Y, the taxpayer must allocate a 
proportionate amount of the common costs of $100,000 to the cost of 
developing and making available the designated drug for both disease X 
and disease Y. Since the ratio of the expected amount of sales in the 
United States of the designated drug for disease X to the total of both 
the expected amount of sales in the United States of the designated drug 
for disease X and the expected amount of sales in the United States of 
the designated drug for disease Y is $500,000/$2,000,000, 25% of the 
common costs of $100,000 (i.e., $25,000) is allocated to the cost of 
developing and making available the designated drug for disease X.
    (iii) Recovery from sales. In determining whether the taxpayer's 
cost described in paragraph (d)(1)(ii) of this section will be recovered 
from sales in

[[Page 95]]

the United States of the designated drug for the disease or condition 
for which the drug is designated, the taxpayer shall include anticipated 
sales by the taxpayer or any person whose right to make such sales is 
directly or indirectly derived from the taxpayer (such as a licensee or 
transferee). The anticipated sales shall be based upon the size of the 
anticipated patient population for which the designated drug would be 
useful, including the following factors: the degree of effectiveness and 
safety of the designated drug, if known: the projected fraction of the 
anticipated patient population expected to be given the designated drug 
and to continue to take it; other available agents and other types of 
therapy; the likelihood that superior agents will become available 
within a few years; and the number of years during which the designated 
drug would be exclusively available, e.g., under a patent.
    (iv) Recordkeeping requirements. The taxpayer shall keep records 
sufficient to substantiate the cost and sales estimates made pursuant to 
this paragraph (d)(1). The records required by this paragraph (d)(1)(iv) 
shall be retained so long as the contents thereof may become material in 
the administration of section 28.
    (2) Tax liability limitation--(i) Taxable years beginning after 
December 31, 1986. The credit allowed by section 28 shall not exceed the 
excess (if any) of--
    (A) The taxpayer's regular tax liability for the taxable year (as 
defined in section 26(b)), reduced by the sum of the credits allowable 
under--
    (1) Section 21 (relating to expenses for household and dependent 
care services necessary for gainful employment),
    (2) Section 22 (relating to the elderly and permanently and totally 
disabled),
    (3) Section 23 (relating to residential energy),
    (4) Section 25 (relating to interest on certain home mortgages), and
    (5) Section 27 (relating to taxes on foreign countries and 
possessions of the United States), over
    (B) The tentative minimum tax for the taxable year (as determined 
under section 55(b)(1)).
    (ii) Taxable years beginning before January 1, 1987, and after 
December 31, 1983. The credit allowed by section 28 shall not exceed the 
taxpayer's tax liability for the taxable year (as defined in section 26 
(b) prior to its amendment by the Tax Reform Act of 1986 (Pub. L. 99-
514)), reduced by the sum of the credits allowable under--
    (A) Section 21 (relating to expenses for household dependent care 
services necessary for gainful employment),
    (B) Section 22 (relating to the elderly and permanently and totally 
disabled),
    (C) Section 23 (relating to residential energy),
    (D) Section 24 (relating to contributions to candidates for public 
office),
    (E) Section 25 (relating to interest on certain home mortgages), and
    (F) Section 27 (relating to the taxes on foreign countries and 
possessions of the United States).
    (iii) Taxable years beginning before January 1, 1984. The credit 
allowed by section 28 shall not exceed the amount of the tax imposed by 
chapter 1 of the Internal Revenue Code for the taxable year, reduced by 
the sum of the credits allowable under the following sections as 
designated prior to the enactment of the Tax Reform Act of 1984 (Pub. 
Law 98-369):
    (A) Section 32 (relating to tax withheld at source on nonresident 
aliens and foreign corporations and on tax-free convenant bonds),
    (B) Sections 33 (relating to taxes of foreign countries and 
possessions of the United States),
    (C) Section 37 (relating to the retirement income),
    (D) Section 38 (relating to investment in certain depreciable 
property),
    (E) Section 40 (relating to expenses of work incentive programs).
    (F) Section 41 (relating to contributions to candidates for public 
office).
    (G) Section 44 (relating to purchase of new principal residence).
    (H) Section 44A (relating to expenses for household and dependent 
care services necessary for gainful employment).
    (I) Section 44B (relating to employment of certain new employees).
    (J) Section 44C (relating to residential energy).
    (K) Section 44D (relating to producing fuel from a nonconventional 
source).

[[Page 96]]

    (L) Section 44E (relating to alcohol used as fuel).
    (M) Section 44F (relating to increasing research activities), and
    (N) Section 44G (relating to employee stock ownership).

The term ``tax imposed by chapter 1'' as used in this paragraph 
(d)(2)(iii) does not include any tax treated as not imposed by chapter 1 
of the Internal Revenue Code under the last sentence of section 53(a).
    (3) Special limitations on foreign testing--(i) Clinical testing 
conducted outside of the United States--In general. Except as otherwise 
provided in this paragraph (d)(3), expenses paid or incurred with 
respect to clinical testing conducted outside the United States (as 
defined in section 7701(a)(9)) are not eligible for credit under this 
section. Thus, for example, wages paid an employee clinical investigator 
for clinical testing conducted in medical facilities in the United 
States and Mexico generally must be apportioned between the clinical 
testing conducted within the United States and the clinical testing 
conducted outside the United States, and only the wages apportioned to 
the clinical testing conducted within the United States are qualified 
clinical testing expenses.
    (ii) Insufficient testing population in the United States--(A) In 
general. If clinical testing is conducted outside of the United States 
because there is an insufficient testing population in the United 
States, and if the clinical testing is conducted by a United States 
person (as defined in section 7701(a)(30)) or is conducted by any other 
person unrelated to the taxpayer to whom the designation under section 
526 of the Federal Food, Drug, and Cosmetic Act applies, then the 
expenses paid or incurred for clinical testing conducted outside of the 
United States are eligible for the credit provided by section 28.
    (B) ``Insufficient testing population.'' The testing population in 
the United States is insufficient if there are not within the United 
States the number of available and appropriate human subjects needed to 
produce reliable data from the clinical investigation.
    (C) ``Unrelated to the taxpayer.'' For the purpose of determining 
whether a person is unrelated to the taxpayer to whom the designation 
under section 526 of the Federal Food, Drug, and Cosmetic Act and the 
regulations thereunder applies, the rules of section 613A(d)(3) shall 
apply except that the number ``5'' in section 613A(d)(3) (A), (B), and 
(C) shall be deleted and the number ``10'' inserted in lieu thereof.
    (4) Special limitations for certain corporations--(i) Corporations 
to which section 936 applies. Expenses paid or incurred for clinical 
testing conducted either inside or outside the United States by a 
corporation to which section 936 (relating to Puerto Rico and 
possessions tax credit) applies are not eligible for the credit under 
section 28.
    (ii) Corporations to which section 934(b) applies. For taxable years 
beginning before January 1, 1987, expenses paid or incurred for clinical 
testing conducted either inside or outside the United States by a 
corporation to which section 934(b) (relating to the limitation on 
reduction in income tax liability incurred to the Virgin Islands), as in 
effect prior to its amendment by the Tax Reform Act of 1986, applies are 
not eligible for the credit under section 28. For taxable years 
beginning after December 31, 1986, see section 1277(c)(1) of the Tax 
Reform Act of 1986 (100 Stat. 2600) which makes the rule set forth in 
the preceding sentence inapplicable with respect to corporations created 
or organized in the Virgin Islands only if (and so long as) an 
implementing agreement described in that section is in effect between 
the United States and the Virgin Islands.
    (5) Aggregation of expenditures--(i) Controlled group of 
corporations; organizations under common control--(A) In general. In 
determining the amount of the credit allowable with respect to an 
organization that at the end of its taxable year is a member of a 
controlled group of corporations or a member of a group of organizations 
under common control, all members of the group are treated as a single 
taxpayer and the credit (if any) allowable to the member is determined 
on the basis of its proportionate share of the qualified clinical 
testing expenses of the aggregated group.

[[Page 97]]

    (B) Definition of controlled group of corporations. For purposes of 
this section, the term ``controlled group of corporations'' shall have 
the meaning given to the term by section 41(f)(5).
    (C) Definition of organization. For purposes of this section, an 
organization is a sole proprietorship, a partnership, a trust, an 
estate, or a corporation, that is carrying on a trade or business 
(within the meaning of section 162). For purposes of this section, any 
corporation that is a member of a commonly controlled group shall be 
deemed to be carrying on a trade or business if any other member of that 
group is carrying on any trade or business.
    (D) Determination of common control. Whether organizations are under 
common control shall be determined under the principles set forth in 
paragraphs (b) through (g) of 26 CFR 1.52-1.
    (ii) Tax accounting periods used--(A) In general. The credit 
allowable to a member of a controlled group of corporations or a group 
of organizations under common control is that member's share of the 
aggregate credit computed as of the end of such member's taxable year.
    (B) Special rule where the timing of clinical testing is 
manipulated. If the timing of clinical testing by members using 
different tax accounting periods is manipulated to generate a credit in 
excess of the amount that would be allowable if all members of the group 
used the same tax accounting period, the district director may require 
all members of the group to calculate the credit in the current taxable 
year and all future years by using the ``conformed years'' method. Each 
member computing a credit under the ``conformed years'' method shall 
compute the credit as if all members of the group had the same taxable 
year as the computing member.
    (iii) Membership during taxable year in more than one group. An 
organization may be a member of only one group for a taxable year. If, 
without application of this paragraph (d)(5)(iii), an organization would 
be a member of more than one group at the end of its taxable year, the 
organization shall be treated as a member of the group in which it was 
included for its preceding taxable year. If the organization was not 
included for its preceding taxable year in any group in which it could 
be included as of the end of its taxable year, the organization shall 
designate in its timely filed return the group in which it is being 
included. If the return for a taxable year is due before May 1, 1985, 
the organization may designate its group membership through an amended 
return for that year filed on or before April 30, 1985. If the 
organization does not so designate, then the district director with 
audit jurisdiction of the return will determine the group in which the 
business is to be included.
    (iv) Intra-group transactions-- (A) In general. Because all members 
of a group under common control are treated as a single taxpayer for 
purposes of determining the credit, transactions between members of the 
group are generally disregarded.
    (B) In-house research expenses. If one member of a group conducts 
clinical testing on behalf of another member, the member conducting the 
clinical testing shall include in its qualified clinical testing 
expenses any in-house research expenses for that work and shall not 
treat any amount received or accrued from the other member as funding 
the clinical testing. Conversely, the member for whom the clinical 
testing is conducted shall not treat any part of any amount paid or 
incurred as a contract research expense. For purposes of determining 
whether the in-house research for that work is clinical testing, the 
member performing the clinical testing shall be treated as carrying on 
any trade or business carried on by the member on whose behalf the 
clinical testing is performed.
    (C) Contract research expenses. If a member of a group pays or 
incurs contract research expenses to a person outside the group in 
carrying on the member's trade or business, that member shall include 
those expenses as qualified clinical testing expenses. However, if the 
expenses are not paid or incurred in carrying on any trade or business 
of that member, those expenses may be taken into account as contract 
research expenses by another member of the group provided that the other 
member--

[[Page 98]]

    (1) Reimburses the member paying or incurring the expenses, and
    (2) Carries on a trade or business to which the clinical testing 
relates.
    (D) Lease payments. Amounts paid or incurred to another member of 
the group for the lease of personal property owned by a person outside 
the group shall be taken into account as in-house research expenses for 
purposes of section 28 only to the extent of the lesser of--
    (1) The amount paid or incurred to the other member, or
    (2) The amount of the lease expense paid to a person outside the 
group.
    The amount paid or incurred to another member of the group for the 
lease of personal property owned by a member of the group is not taken 
into account for purposes of section 28.
    (E) Payment for supplies. Amounts paid or incurred to another member 
of the group for supplies shall be taken into account as in-house 
research expenses for purposes of section 28 only to the extent of the 
lesser of--
    (1) The amount paid or incurred to the other member, or
    (2) The amount of the other member's basis in the supplies.
    (6) Allocations--(i) Pass-through in the case of an S corporation. 
In the case of an S corporation (as defined in section 1361), the amount 
of the credit for qualified clinical testing expenses computed for the 
corporation for any taxable year shall be allocated among the persons 
who are shareholders of the corporation during the taxable year 
according to the provisions of section 1366 and section 1377.
    (ii) Pass-through in the case of an estate or a trust. In the case 
of an estate or a trust, the amount of the credit for qualified clinical 
testing expenses computed for the estate or trust for any taxable year 
shall be apportioned between the estate or trust and the beneficiaries 
on the basis of the income of the estate or trust allocable to each.
    (iii) Pass-through in the case of a partnership--(A) In general. In 
the case of a partnership, the credit for qualified clinical testing 
expenses computed for the partnership for any taxable year shall be 
apportioned among the persons who are partners during the taxable year 
in accordance with section 704 and the regulations thereunder.
    (B) Certain partnership non-business expenditures. A partner's share 
of an in-house research expense or contract research expense paid or 
incurred by a partnership other than in carrying on a trade or business 
of the partnership constitutes a qualified clinical testing expense of 
the partner if--
    (1) The partner is entitled to make independent use of the result of 
the clinical testing, and
    (2) The clinical testing expense paid or incurred in carrying on the 
clinical testing would have been paid or incurred by the partner in 
carrying on a trade or business of the partner if the partner had 
carried on the clinical testing that was in fact carried on by the 
partnership.
    (C) Apportionment. Qualified clinical testing expenses to which 
paragraph (d)(6)(iii)(B) of this section applies shall be apportioned 
among the persons who are partners during the taxable year in accordance 
with section 704 and the regulations thereunder. For purposes of section 
28, these expenses shall be treated as paid or incurred directly by the 
partners rather than by the partnership. Thus, the partnership shall 
disregard these expenses in computing the credit to be apportioned under 
paragraph (d)(6)(iii)(A) of this section, and each partner shall 
aggregate the portion of these expenses allocated to the partner with 
other qualified clinical testing expenses of the partner in making the 
computations under section 28.
    (iv) Year in which taken into account. An amount apportioned to a 
person under paragraph (d)(6) of this section shall be taken into 
account by the person in the taxable year of such person in which or 
with which the taxable year of the corporation, estate, trust, or 
partnership (as the case may be) ends.
    (v) Credit allowed subject to limitation. Any person to whom any 
amount has been apportioned under paragraph (d)(6)(i), (ii), or (iii) of 
this section is allowed, subject to the limitation provided in section 
28(d)(2), a credit for that amount.
    (7) Manner of making an election. To make an election to have 
section 28

[[Page 99]]

apply for its taxable year, the taxpayer shall file Form 6765 (Credit 
for Increasing Research Activities (or for claiming the orphan drugs 
credit)) containing all the information required by that form.

[T.D. 8232, 53 FR 38711, Oct. 3, 1988; 53 FR 40879, Oct. 19, 1988; 53 FR 
41013, Oct. 19, 1988]

                           Credits Against Tax

             credits allowable under sections 30 through 45D